Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $142,940.48 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the sale, the chief operating officer now owns 323,310 shares of the company’s stock, valued at approximately $6,931,766.40. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31.
• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded up $0.42 during trading hours on Tuesday, hitting $20.69. The stock had a trading volume of 212,908 shares, compared to its average volume of 235,378. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -10.89 and a beta of 1.04. The company has a 50 day simple moving average of $21.80 and a two-hundred day simple moving average of $23.88.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. FMR LLC boosted its stake in shares of Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after purchasing an additional 199,692 shares during the period. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after purchasing an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA raised its position in Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock valued at $21,877,000 after purchasing an additional 135,969 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ELVN. BTIG Research started coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Robert W. Baird increased their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.